Hey Forrest,Yes CST is still on my watchlist, but SDI continues...

Hey Forrest,

Yes CST is still on my watchlist, but SDI continues to be the one earning the real sales and outperforming for the time being.

All in all a positive announcement, but with a twist or two. In the interest of balanced reporting don't forget to mention the upfront payments CST have agreed to make (from memory that's a fair chunk of their remaining cash, especially on top of current year's cash burn and slowness of securing sales of Mark 1 test), and also the very significant royalty payments (8-15.5% of revenue - note, not of profits) that are slated.

Also, perhaps, a heightening concern that BCG corruption is causing a problem (perception among clinicians) with getting Mark 1 test off and running ?

What is your take on timing of regulatory approvals ? "Clinical trials proceeding" is mentioned - two years minimum ?


Jess.